OmniAb to Participate in Upcoming Investor Conferences in November
OmniAb to Participate in Upcoming Investor Conferences in November
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management’s participation in the following upcoming investor conferences:
Stifel Healthcare Conference
Date: Wednesday, November 11, 2026
2026 Truist Securities BioPharma Symposium
Date: Thursday, November 12, 2026
Jefferies London Healthcare Conference
Date: November 16–19, 2026
Craig-Hallum Investor Conference
Date: Tuesday, November 17, 2026
The Stifel Healthcare Conference, Truist Securities BioPharma Symposium, and Craig-Hallum Investor Conference will take place in New York City. The Jefferies London Healthcare Conference will take place in London, UK.
Management will be available for one-on-one meetings with investors at each conference. Interested investors should contact the conference organizers or email investor relations.
About OmniAb
OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. These technologies paired with xPloration, our AI-powered high-throughput single B-cell screening platform, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
OmniAb, Inc.
investors@OmniAb.com
X@OmniAbTech
Alliance Advisors IR
Vivian Cervantes
vcervantes@allianceadvisors.com
(973) 873-7724
View source version on businesswire.com: https://www.businesswire.com/news/home/20261026743694/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States